IN2013MN00567A - - Google Patents

Info

Publication number
IN2013MN00567A
IN2013MN00567A IN567MUN2013A IN2013MN00567A IN 2013MN00567 A IN2013MN00567 A IN 2013MN00567A IN 567MUN2013 A IN567MUN2013 A IN 567MUN2013A IN 2013MN00567 A IN2013MN00567 A IN 2013MN00567A
Authority
IN
India
Prior art keywords
agonist
inhibitor
kinase inhibitor
product
receptor
Prior art date
Application number
Other languages
English (en)
Inventor
Peter Robert Hansen
Svetlana Ivanova
Frank Burkamp
Original Assignee
Astrazeneca Ab
Astrazeneca Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Astrazeneca Uk Ltd filed Critical Astrazeneca Ab
Publication of IN2013MN00567A publication Critical patent/IN2013MN00567A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IN567MUN2013 2010-10-07 2011-10-05 IN2013MN00567A (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1016912.6A GB201016912D0 (en) 2010-10-07 2010-10-07 Novel combination
PCT/GB2011/051898 WO2012046050A1 (en) 2010-10-07 2011-10-05 Novel combinations

Publications (1)

Publication Number Publication Date
IN2013MN00567A true IN2013MN00567A (sr) 2015-10-09

Family

ID=43304217

Family Applications (1)

Application Number Title Priority Date Filing Date
IN567MUN2013 IN2013MN00567A (sr) 2010-10-07 2011-10-05

Country Status (14)

Country Link
EP (1) EP2624838A1 (sr)
JP (1) JP2013538867A (sr)
KR (1) KR20130126595A (sr)
CN (1) CN103249418A (sr)
AU (1) AU2011311310A1 (sr)
BR (1) BR112013008362A2 (sr)
CA (1) CA2813684A1 (sr)
GB (1) GB201016912D0 (sr)
IL (1) IL225312A0 (sr)
IN (1) IN2013MN00567A (sr)
MX (1) MX2013003816A (sr)
RU (1) RU2013115103A (sr)
SG (1) SG188575A1 (sr)
WO (1) WO2012046050A1 (sr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150027922A (ko) * 2013-09-04 2015-03-13 주식회사 대웅제약 신규한 항진균성 피리디닐하이드라자이드 유도체
KR101657678B1 (ko) * 2013-11-05 2016-09-20 주식회사 대웅제약 신규한 화합물, 이의 제조방법 및 이를 포함하는 항진균제 조성물
US10927128B2 (en) * 2015-11-16 2021-02-23 Esteve Pharmaceuticals. S.A. Oxadiazaspiro compounds for the treatment of drug abuse and addiction
CN109195975B (zh) * 2016-09-30 2022-01-04 四川海思科制药有限公司 一种二氮杂螺[5.5]十一碳烷衍生物及其用途
CN117024499A (zh) * 2023-07-17 2023-11-10 陕西汉江药业集团股份有限公司 在2位引入亚甲基羟基的甾体化合物制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
SE0102617D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
RU2312854C2 (ru) 2001-09-14 2007-12-20 Глаксо Груп Лимитед Производные фенэтаноламина для лечения респираторных заболеваний
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
TW200409746A (en) 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
OA12938A (en) 2002-10-11 2006-10-13 Pfizer Indole derivatives as beta-2 agonists.
EP1556342B1 (en) 2002-10-28 2008-03-26 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
SE0300092D0 (sv) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300091D0 (sv) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
EP1626970B1 (en) 2003-05-28 2009-07-08 Theravance, Inc. Azabicycloalkane compounds as muscarinic receptor antagonists
TW200526547A (en) 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
JP4851937B2 (ja) 2003-11-21 2012-01-11 セラヴァンス， インコーポレーテッド β２アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物
GB0402797D0 (en) 2004-02-09 2004-03-10 Novartis Ag Organic compounds
US7745621B2 (en) 2004-05-14 2010-06-29 Boehringer Ingelheim International Gmbh Long acting bronchodilators for the treatment of respiratory diseases
DE102004024453A1 (de) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
US7402673B2 (en) 2004-06-03 2008-07-22 Theravance, Inc. Diamine β2 adrenergic receptor agonists
US20060002967A1 (en) 2004-07-01 2006-01-05 Smestad Thomas L Resorbable implant with lubricious coating
EP1833822A2 (en) 2004-08-16 2007-09-19 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP1778626A1 (en) 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
GB0425057D0 (en) 2004-11-12 2004-12-15 Pfizer Ltd L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]eth yl}amino)propyl]phenyl}acetamide
US20060114254A1 (en) 2004-11-26 2006-06-01 Tim Day Volume rendering apparatus and method
WO2006066907A1 (en) 2004-12-21 2006-06-29 Glaxo Group Limited Pharmaceutical formulations
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
GB0512246D0 (en) 2005-06-15 2005-07-27 Glaxo Group Ltd Novel pharmaceutical
EA016203B1 (ru) 2006-03-20 2012-03-30 Пфайзер Лимитед Производные амина
ES2296516B1 (es) 2006-04-27 2009-04-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
ATE505193T1 (de) 2006-08-07 2011-04-15 Boehringer Ingelheim Int Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
PE20081358A1 (es) 2006-08-22 2008-10-31 Boehringer Ingelheim Int Combinaciones farmacologicas para el tratamiento de enfermedades de la vias aereas
BRPI0719270A2 (pt) 2006-10-04 2014-03-11 Pfizer Ltd Derivados de sulfonamida como agonistas adrenérgicos e antagonistas muscarínicos
ES2302447B1 (es) 2006-10-20 2009-06-12 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
JO2754B1 (en) 2006-12-21 2014-03-15 استرازينكا ايه بي Amylendazoleil derivatives for the treatment of glucocorticoid-mediated disorders
SA08280783B1 (ar) 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
ES2306595B1 (es) 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
WO2008106016A2 (en) 2007-02-27 2008-09-04 Metrosol, Inc. Prism spectrometer with moveable detector element and with collimated input light
GB0703999D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab New combination 667
JP5140154B2 (ja) 2007-06-27 2013-02-06 アストラゼネカ・アクチエボラーグ ピラジノン誘導体および肺疾患の処置におけるそれらの使用
AU2008306593C1 (en) * 2007-10-04 2012-10-04 Astrazeneca Ab Steroidal [3, 2-C] pyrazole compounds, with glucocorticoid activity
PT2242759E (pt) 2008-02-06 2012-12-17 Astrazeneca Ab Compostos
AU2009247021B2 (en) 2008-05-13 2012-06-07 Astrazeneca Ab Pharmaceutical product comprising a muscarinic receptor antagonist and a beta2-adrenoceptor agonist
WO2009138707A1 (en) 2008-05-13 2009-11-19 Astrazeneca Ab Quinuclidine derivatives as muscarinic m3 receptor antagonists
UY32520A (es) 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802

Also Published As

Publication number Publication date
IL225312A0 (en) 2013-06-27
MX2013003816A (es) 2013-05-01
JP2013538867A (ja) 2013-10-17
SG188575A1 (en) 2013-04-30
KR20130126595A (ko) 2013-11-20
WO2012046050A1 (en) 2012-04-12
AU2011311310A1 (en) 2013-04-11
GB201016912D0 (en) 2010-11-24
CA2813684A1 (en) 2012-04-12
RU2013115103A (ru) 2014-11-20
EP2624838A1 (en) 2013-08-14
BR112013008362A2 (pt) 2016-06-14
CN103249418A (zh) 2013-08-14

Similar Documents

Publication Publication Date Title
BR112013008140A2 (pt) "compostos imidazotriazinona".
IL207440A (en) Use of an antagonist antibody against a related peptide-calcitonin gene (cgrp) in the preparation of a drug for the prevention and / or treatment of chronic pain and / or symptoms of chronic pain and pharmaceutical preparations and kits containing it
MX2009008363A (es) Combinacion de un antagonista de receptor muscarinico y un agonista de receptor adrenergico beta 2.
IL199045A0 (en) Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
EP2813223B8 (en) Metal delivery agents and therapeutic uses of the same
DE602007006961D1 (de) Cgrp-rezeptorantagonisten
MY162895A (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
UY32521A (es) Combinación para emplear en el tratamiento de enfermedades respiratorias
EP3974453A3 (en) Agents and methods for treating diseases that correlate with bcma expression
WO2009050136A3 (en) Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
CL2011002056A1 (es) Compuestos derivados del acido {7-([1,2,3]triazol-1-il)-6,7,8,9-tetrahidropirido[1,2-a]indol-10-il}-acetico, antagonista del receptor crth2; composicion farmaceutica que lo comprende; utiles ene l tratamiento del asma, alergias, cancer entre otras.
PL2079446T3 (pl) Preparat paliperidonu o przedłużonym uwalnianiu
HK1206726A1 (en) Imidazotriazinone compounds
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
HK1207304A1 (en) Crhr1 antagonists for use in the treatment of patients having crh overactivity
WO2008049842A3 (en) Egfr kinase inhibitor combinations for the treatment of respiratory and gastrointestinal disorders
IN2013MN00567A (sr)
SG195262A1 (en) Combination comprising umeclidinium and a corticosteroid
NZ714288A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
WO2011101634A3 (en) Methods of prevention or treatment of triggered inflammatory reactions using tumor necrosis factor alpha antagonist
IL200375A0 (en) Remedy for chemotherapy-resistant cancer containing hla class-i-recognizing antibody as the active ingredient and use of the same
SI1863476T1 (sl) Kombinacija antiholinergikov in antagonistov receptorja levkotriena za zdravljenje respiratornih bolezni
WO2010033167A3 (en) Anti-thrombin aptamer formulations and methods for use